Is Ac-SDKP FDA approved?

Ac-SDKP is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

KPV is the subject of a favorable FDA advisory committee vote but not FDA approved, and its legal status for compounding is unchanged. It is discussed for research and educational purposes only, not as medical guidance.

How is Ac-SDKP administered in research settings?

In research settings, Ac-SDKP is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is KPV administered in research settings?

In research settings, KPV is typically administered via the oral, subcutaneous, or topical routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Ac-SDKP vs KPV

Peptide Comparison

Ac-SDKP vs KPV

Q: What is the difference between Ac-SDKP and KPV?

Ac-SDKP: Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme. KPV: Derived from alpha-MSH; binds melanocortin receptors MC1R/MC3R to suppress NF-κB and inflammatory cytokines

Both are Tissue Repair peptides.

Ac-SDKP

N-acetyl-seryl-aspartyl-lysyl-proline

RecoveryNot EvaluatedResearch Only

No providers listed yet

Full Ac-SDKP profile →

KPV

Lys-Pro-Val

RecoveryAdvisory Vote: FavorableResearch Only

Half-life: Short (minutes to hours)

105 providers listed

Full KPV profile →

Bottom line

KPV is carried by more providers on PeptideBase (105 vs 0); otherwise the two are closely matched on the measures we track.

Quick Verdict

Ac-SDKP

KPV

Which One Should You Choose?

Your goal	Better option
Oral administration option	KPV
More provider options (0 vs 105)	KPV

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Ac-SDKP

KPV

Mechanism Family

Tissue Repair

Half-life

—

Short (minutes to hours)

FDA Status

not evaluated

advisory committee recommended

Admin Routes

subcutaneous, intravenous

oral, subcutaneous, topical

Availability

Research Only

Providers

None listed

105 listed

FDA Update

—

Jul 2026

Avail. Notes

—

Alpha-MSH C-terminal tripeptide fragment (Lys-Pro-Val). Anti-inflammatory. No FDA approval, no NDA or IND. Not on any FDA list. Research chemical only.

Research Evidence

Ac-SDKP

Animal · 3 key studies · most recent 2026

KPV

Review · 3 key studies · most recent 2026

Research Citations

Ac-SDKP

Animal2026 · Biomater Adv

Device surface-functionalized ac-SDKP nanoassemblies accelerate endothelial recovery through dual anti-inflam…

Animal2015 · American Journal of Physiology: Renal Physiology

N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythe…

Animal2013 · Kidney International

Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis

KPV

Animal2017 · Molecular Therapy

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Allev…

Animal2008 · Gastroenterology

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

Review2026 · J Sports Med Phys Fitness

A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodyb…

About Ac-SDKP

Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme.

Research Areas

anti-fibroticcardiac repairwound healingkidney protection

About KPV

Derived from alpha-MSH; binds melanocortin receptors MC1R/MC3R to suppress NF-κB and inflammatory cytokines

Research Areas

anti-inflammatorygut healingwound healing

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Ac-SDKP

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

KPV

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Find Providers

Where to source these peptides

Providers offering

Ac-SDKP

Browse directory →

Providers offering

KPV

105 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Tissue Repair Comparisons

Browse all peptides →

Educational research tools — not medical advice.